RAF1 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC) models in particular, ganetespib effectively destabilizes a number of oncogenic drivers, including the KRAS effector CRAF and PDGFRα, that in turn inactivates downstream MAPK and AKT signaling to induce apoptosis [16].